Hirtle Callaghan & Co’s Boston Scientific BSX Stock Holding History

Hirtle Callaghan & Co’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-104,047	Closed	-$1.38M	–	65
2014 Q4	$1.38M	Buy	+104,047	New	+$1.33M	0.32%	54
2014 Q3	–	Sell	-104,047	Closed	-$1.33M	–	568
2014 Q2	$1.33M	Hold	104,047	–	–	0.18%	78
2014 Q1	$1.41M	Hold	104,047	–	–	0.23%	58
2013 Q4	$1.25M	Hold	104,047	–	–	0.17%	67
2013 Q3	$1.22M	Buy	+104,047	New	+$1.13M	0.2%	64

Other funds holding BSX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return

Hirtle Callaghan & Co's BSX Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of Boston Scientific (BSX) in Q1 2015, closing a stake of 104,047 shares — an estimated $1.38M sold.

Hirtle Callaghan & Co first reported a position in BSX in Q3 2013 and held it in 5 quarters. The position peaked at $1.41M in Q1 2014. 471 funds tracked by Wall St. Rank hold BSX as of Q1 2015.

Hirtle Callaghan & Co reported no remaining Boston Scientific position as of Q1 2015 after selling out during the quarter.
Hirtle Callaghan & Co sold 104,047 Boston Scientific shares in Q1 2015, an estimated $1.38M.
Hirtle Callaghan & Co first reported a position in Boston Scientific in Q3 2013 and held it in 5 quarters.
Hirtle Callaghan & Co's Boston Scientific position peaked at $1.41M in Q1 2014.
471 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.